We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

2 hedge funds and large institutions have $7.03M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $738K | Put options by funds: $408K

2% more capital invested

Capital invested by funds: $6.92M → $7.03M (+$111K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
$738K
Puts
$408K
Net Calls
+$330K
Net Calls Change
+$518K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DIA
Denver Investment Advisors
Colorado
-$150K
2
VKH
Virtu KCG Holdings
New York
-$38K
3
Goldman Sachs
Goldman Sachs
New York
-$28K
4
Millennium Management
Millennium Management
New York
-$24K
5
WA
WFG Advisors
Texas
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.52M – – –
VAM
2
Visium Asset Management
New York
$2.48M – – –
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$581K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$284K – – –
BFA
5
BlackRock Fund Advisors
California
$278K – – –
Northern Trust
6
Northern Trust
Illinois
$142K – – –
Bank of New York Mellon
7
Bank of New York Mellon
New York
$113K – – –
CC
8
Callan Capital
California
$97K – – –
HighTower Advisors
9
HighTower Advisors
Illinois
$87K – – –
HCM
10
Highlander Capital Management
New Jersey
$65.3K – – –
RCM
11
Rotella Capital Management
Washington
$60K – – –
RG
12
Rathbones Group
United Kingdom
$56K – – –
Deutsche Bank
13
Deutsche Bank
Germany
$36K – – –
GC
14
Guggenheim Capital
Illinois
$35K – – –
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$33K – – –
State Street
16
State Street
Massachusetts
$26K – – –
BA
17
BlackRock Advisors
Delaware
$25K – – –
RC
18
Randolph Company
Ohio
$23K – – –
SM
19
Sabby Management
Florida
$23K – – –
FANJ
20
Financial Architects (New Jersey)
New Jersey
$18K – – –
BIM
21
BlackRock Investment Management
Delaware
$14K – – –
AIG
22
American International Group
New York
$13.8K – – –
Morgan Stanley
23
Morgan Stanley
New York
$8K – – –
Citigroup
24
Citigroup
New York
$6K – – –
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3K – – –
1
2

SEEL Hedge Fund Activity: Q2 2014 in Review

2 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2014, worth a combined $7.03M — up 1.6% from $6.92M a quarter earlier.

Fund positioning in SEEL was balanced in Q2 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Denver Investment Advisors, cutting an estimated $150K.

  • 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $7.03M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2014, up 1.6% quarter-over-quarter.
  • 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2014 and 0 closed out.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2014 was Denver Investment Advisors, an estimated $150K sold.

Based on aggregated 13F filings for Q2 2014.